From Discovery to Recovery
New compounds in development by the biotech and pharmaceutical industries may hold
the promise of future medical treatments and cures. At Grace, we pride ourselves
in the contributions we have made, and will continue to make, in facilitating the
processes that lead to these discoveries—and ultimately, to the manufacturing processes
that will bring these new drugs to market.
For start-up companies, well-established biotech and pharmaceutical firms and educational
institutions alike, the process begins in the laboratory, where compounds are discovered
and meticulously researched. Grace analytical HPLC columns have played a key role
in many of these initial discovery-phase enterprises.
Once promising compounds have been identified and isolated, the next phase begins,
producing the quantities necessary for clinical trials. Many successful companies
have scaled up to Grace preparative chromatography columns in this phase, knowing
the performance, quality and reliability they depended on during discovery continues
with a truly scalable silica platform.
When successful clinical trials ultimately yield new blockbuster drugs, Grace remains
a partner in the process. Once the Food and Drug Administration has approved a new
drug, companies are poised for the transition to process scale production and market
introduction. Grace is ready to provide the bulk materials and appropriate regulatory
support documentation for our products, plus the technical support required to start
packing larger columns for the manufacturing environment.
A number of large, well-known biotech and pharmaceutical companies have partnered
with Grace throughout their discovery-to-recovery processes. They knew they could
count on Grace's strong manufacturing control of the bulk silica and bonding chemistries
to provide a consistent product at any scale.
DiscoverySciences.com